Eleven Biotherapeutics Inc. (NASDAQ:EBIO) shares traded down 5.9% during mid-day trading on Wednesday . The company traded as low as $2.05 and last traded at $2.09, with a volume of 959,599 shares trading hands. The stock had previously closed at $2.22.

The stock’s 50-day moving average price is $1.79 and its 200 day moving average price is $1.12. The firm’s market capitalization is $31.25 million.

In other news, major shareholder Boxer Capital, Llc sold 1,042,000 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $2.74, for a total transaction of $2,855,080.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.